

Supplementary material to
Improving genomics-based predictions for precision medicine through active elicitation of expert knowledge

Iiris Sundin, Tomi Peltola, Luana Micallef, Homayun Afrabandpey, Marta Soare, Muntasir Mamun Majumder, Pedram Daee, Chen He, Baris Serim, Aki Havulinna, Caroline Heckman, Giulio Jacucci, Pekka Marttinen and Samuel Kaski

1 Metabolite concentration prediction from genomic data – supplementary results

Table 1: Metabolite concentration prediction from genomic data, MSE results by metabolite.

| | HDL-C | LDL-C | TC | TG |
|--------------|-------|-------|-------|-------|
| Data mean | 0.996 | 1.028 | 0.996 | 1.049 |
| Elastic net | 0.984 | 1.028 | 0.996 | 1.033 |
| No feedback | 0.978 | 1.009 | 0.984 | 1.025 |
| All feedback | 0.960 | 0.998 | 0.970 | 1.010 |

Table 2: Metabolite concentration prediction from genomic data, C-index results by metabolite.

| | HDL-C | LDL-C | TC | TG |
|--------------|-------|-------|-------|-------|
| Data mean | 0.500 | 0.500 | 0.500 | 0.500 |
| Elastic net | 0.534 | 0.500 | 0.500 | 0.542 |
| No feedback | 0.541 | 0.537 | 0.537 | 0.546 |
| All feedback | 0.561 | 0.555 | 0.552 | 0.564 |




Figure 1: A sensitivity analysis with regard to the sparsity parameter ρ and the effect size parameter τ^2 . The heatmap shows the proportion of variance explained on the test set for no feedback (left part of each heatmap) and all feedback (right part) models. ρ values are 0.001, 0.006, 0.011, 0.016, 0.021, 0.026, 0.030, 0.035, 0.040, 0.045, 0.050 and τ^2 values are 0.001, 0.011, 0.021, 0.031, 0.041, 0.051, 0.060, 0.070, 0.080, 0.090, 0.100.

2 Drug sensitivity prediction for Multiple Myeloma (MM) patients – supplementary results

Table 3: Drug sensitivity prediction for Multiple Myeloma (MM) patients, MSE results by drug.

| | Pimasertib | Refametinib | Trametinib | Dexamethasone | Methylprednisolone | AZD2014 | Dactolisib | Idelalisib | PF-04691502 | Pictilisib | Temsirolimus | Venetoclax |
|-----------------|------------|-------------|------------|---------------|--------------------|---------|------------|------------|-------------|------------|--------------|------------|
| Data mean | 1.083 | 1.080 | 1.081 | 1.093 | 1.090 | 1.056 | 1.057 | 1.131 | 1.065 | 1.052 | 1.074 | 1.084 |
| Elastic net | 1.084 | 1.172 | 1.070 | 1.127 | 1.204 | 1.185 | 1.219 | 1.215 | 1.212 | 1.179 | 1.041 | 1.133 |
| No feedback | 1.031 | 1.030 | 1.019 | 1.080 | 1.079 | 1.034 | 1.025 | 1.138 | 1.059 | 1.042 | 1.003 | 1.055 |
| All feedback DC | 1.026 | 1.030 | 1.011 | 1.075 | 1.078 | 1.013 | 1.004 | 1.134 | 1.043 | 1.022 | 0.992 | 1.055 |
| All feedback SR | 0.982 | 0.989 | 0.970 | 1.082 | 1.087 | 0.985 | 0.982 | 1.174 | 1.028 | 1.011 | 0.954 | 1.057 |

Table 4: Drug sensitivity prediction for Multiple Myeloma (MM) patients, C-index results by drug.

| | Pimasertib | Refametinib | Trametinib | Dexamethasone | Methylprednisolone | AZD2014 | Dactolisib | Idelalisib | PF-04691502 | Pictilisib | Temsirolimus | Venetoclax |
|-----------------|------------|-------------|------------|---------------|--------------------|---------|------------|------------|-------------|------------|--------------|------------|
| Data mean | 0.500 | 0.500 | 0.500 | 0.500 | 0.500 | 0.500 | 0.500 | 0.500 | 0.500 | 0.500 | 0.500 | 0.500 |
| Elastic net | 0.509 | 0.493 | 0.557 | 0.484 | 0.448 | 0.520 | 0.451 | 0.527 | 0.493 | 0.441 | 0.565 | 0.574 |
| No feedback | 0.605 | 0.632 | 0.629 | 0.542 | 0.542 | 0.569 | 0.580 | 0.502 | 0.536 | 0.536 | 0.617 | 0.632 |
| All feedback DC | 0.556 | 0.572 | 0.605 | 0.554 | 0.533 | 0.594 | 0.583 | 0.548 | 0.589 | 0.576 | 0.638 | 0.638 |
| All feedback SR | 0.619 | 0.637 | 0.657 | 0.564 | 0.520 | 0.638 | 0.626 | 0.443 | 0.597 | 0.604 | 0.665 | 0.596 |